Relay Therapeutics offers a high-risk, high-upside precision oncology bet, with zovegalisib’s Phase 3 success poised to determine whether its Dynamo platform becomes a commercial breakthrough or remains a compelling but unproven biotech story.
Overview
Relay Therapeutics is a pre-commercial clinical-stage biotech using its Dynamo platform to design highly selective precision medicines targeting protein motion. Its lead asset, zovegalisib, is in Phase 3 for PIK3CA-mutant HR+/HER2- metastatic breast cancer and Phase 2 for vascular anomalies. Lirafugratinib is out-licensed to Elevar with potential milestones and royalties. The thesis rests on differentiated efficacy, reduced toxicity, first-mover clinical positioning, and large oncology and rare disease markets.